June 30, 2020 Henric Bjarke Dear Henric:Letter Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This letter (the “Letter Agreement”) amends and restates the terms and conditions of your employment with Inozyme Pharma, Inc. (“Inozyme” or the “Company”), as initially set forth in the offer letter dated June 22, 2017 and as amended if applicable (the “Original Offer Letter”), and will take effect upon the closing of the Company’s initial public offering (the “Effective Date”), provided that you remain employed by the Company as of the Effective Date. Until the Effective Date, the Original Offer Letter will remain in full force and effect and continue to govern your employment with the Company. This Letter Agreement contains the following terms:
INOZYME PHARMA, INC. STOCK OPTION AGREEMENT GRANTED UNDER AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLANStock Option Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations
This Stock Option Agreement (this “Agreement”) is made between Inozyme Pharma, Inc., a Delaware corporation (the “Company”), and the Participant pursuant to the Amended and Restated 2017 Equity Incentive Plan (the “Plan”).
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Connecticut
THIS LICENSE AGREEMENT (this “AGREEMENT”), dated as of January 6, 2017 (the “EFFECTIVE DATE”), by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and INOZYME PHARMA, LLC, a limited liability company formed and existing under the laws of the State of Delaware, and with principal offices located at [**] (“LICENSEE”) is effective as of the EFFECTIVE DATE.
INOZYME PHARMA, LLC REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT, dated as of June 1, 2016 (this “Agreement”), by and among Inozyme Pharma, LLC, a Delaware limited liability company (the “Company”), and holders of the Company’s Class 1 Stock (the “Class 1 Stock”), listed on Exhibit A (together with certain other persons who become parties as provided herein, the “Holders”).
INOZYME PHARMA, LLC RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS RESTRICTED STOCK AGREEMENT, dated as of the date set forth on Exhibit A hereto (this “Agreement”), by and between Inozyme Pharma, LLC, a Delaware limited liability company (the “Company”), and the person named in Exhibit A hereto (the “Purchaser”).
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL...Corporate Sponsored Research Agreement • July 2nd, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Connecticut
This RESEARCH AGREEMENT (this “Agreement”) is entered into as of January 6, 2017 (the “Effective Date”), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”), and Inozyme Pharma, LLC, a Delaware limited liability company, having its principal offices at [**] (the “Sponsor”).
